Scientific Advisory Committee

Dr. Richard Deth

Professor of Pharmacology in the Department of Pharmaceutical Sciences at Nova Southeastern University and Professor Emeritus at Northeastern University

Dr. Richard Deth received his B.S. degree in Pharmacy from State University of New York at Buffalo, and his doctoral degree in Pharmacology from the University of Miami. His research interests are focused on the role of oxidative stress and impaired methylation reactions in neurodevelopmental, neuropsychiatric and neurodegenerative disorders, including the important role of epigenetic regulation. His laboratory was first to identify the unique ability of the D4 dopamine receptor to carry out phospholipid methylation and showed that numerous environmentally-derived toxins, including heavy metals, potently impair this process as well as other methylation reactions.

Dr. Deth has published more than 100 peer reviewed research articles and book chapters and in 2003 he authored the monograph “Molecular Origins of Human Attention: The Dopamine-Folate Connection”. In recent years his work has focused understanding the factors contributing to the current autism epidemic. This ongoing work includes investigations of the status of the antioxidant glutathione and vitamin B12, the influence of morphine and gluten/casein-derived opioid peptides on redox and methylation status, and the emerging role of the gasotransmitter hydrogen sulfide in brain disorders across the lifespan.


George W. Lucier, Ph.D

Toxicologist, Retired Director of the Environmental Toxicology Program, National Institutes of Environmental Health Sciences
Dr. Lucier’s credentials and record of accomplishments in the field of toxicology are impressive and well-documented. He retired from the National Institute of Environmental Health Sciences in 2000 where he was Director of the Environmental Toxicology program and Associate Director of the National Toxicology Program. In that capacity, Dr. Lucier was responsible for coordinating toxicological research and testing across Federal agencies including the U.S Environmental Protection Agency, the Food and Drug Administration, the Occupational Safety and Health Administration and parts of the Centers for Disease Control. Dr. Lucier was head of a research group in molecular epidemiology and risk assessment and has authored approximately 250 scientific publications. His research focused on the use of basic biology to reduce uncertainty in human risk assessments and to improve the tools used in exposure assessment. His work has made major contributions to risk assessments for dioxins, endocrine disrupters and methylmercury and he is frequently asked by Federal agencies to assist them in high visibility risk assessments.

Dr. Lucier chairs the Science Advisory Board for hazardous air pollutants for the State of North Carolina which makes recommendations on safe exposure levels on air pollutants of concern to North Carolina. He is also an advisor to the National Institutes of Health, a member of the NAS Committee on Toxicity Testing and a member of the Science Advisory Board for EPA. Dr. Lucier was editor of the scientific journal, Environmental Health Perspectives, for 28 years.


Professor Luc Montagnier, M.D., Ph.D

Nobel Prize Recipient, Co-founder CHRONIMED, President of the World Foundation for Aids Research and Prevention
Professor Luc Montagnier graduated in both Medicine and Biological Sciences at the University of Paris. At the age of 23, he became Assistant at this University. After a fruitful post-doctoral stay in two British laboratories, he spent most of his scientific career in two renowned French Institutions, the Institut Curie and the Institut Pasteur in Paris. Within the new Department of Virology of the latter Institute, he founded the Viral Oncology Research Unit which devoted its activities to 1) the study of cancer viruses, mostly the oncogenic retroviruses and 2) the biochemical aspects of interferon and of malignant transformation, including membrane changes in relation with the growth in soft agar, a new property of cultured malignant cells.

In 1983, he led the team which first isolated the Human Immunodeficiency Virus (HIV1) and brought the first evidence that this virus was the causative agent of AIDS. In 1985, he also isolated the second AIDS virus, HIV2, from West African patients. His laboratory was also the first to show that a large fraction of white blood cells of HIV infected patients were prone to die by apoptosis, a process of programmed cell death and to attribute its origin to the oxidative stress occurring in the patients, possibly associated with co-infections.

Professor Montagnier’s current studies are aimed at the diagnosis and treatment of microbial and viral factors associated with cancers, neurodegenerative and articular diseases, using innovative technologies. As a strong advocate of preventive medicine, he is especially concerned with prolonging the active life of aging people.

Beyond his scientific interest is his deep involvement with helping developing countries to acquire knowledge of and access to modern medicine and preventive medicine. As President of the World Foundation for Aids Research and Prevention, he has co-founded two Centers for the prevention, treatment, research and diagnosis of AIDS patients in Ivory Coast and Cameroon.

Ten years ago, Professeur Montagnier co-founded CHRONIMED, an international group of physicians treating chronic diseases, including but not limited to autism spectrum disorders, Alzheimers, Lyme, multiple scleroses, and cancer. Various treatment modalities are used for these multi-factorial conditions. Most of these treatments were developed upon the research of Montagnier and his Chronimed associates. Foundation Luc Montagnier in Geneva, Switzerland does cutting-edge research, bringing in international investigators in various fields. The Foundation has on its premises associated Chronimed clinicians.

Luc Montagnier has been awarded many prizes including Prizes Rosen (1971), Gallien (1985), Korber (1986), Jeantet (1986), the Lasker Prize in Medicine (1986), the Gairdner Prize (1987), Santé Prize (1987), Japan Prize (1988), King Faisal Prize (1993), Amsterdam Foundation Prize (1994), Warren Alpert Prize (1998), Prince of Asturias Award (2000) the induction to the National Invention Hall of Fame (2004). He is Commandeur de l’Ordre National du Mérite (1986) and Grand Officier of the Legion of Honour (2009).

In 2008, he was awarded the Nobel Prize for Physiology and Medicine, for his discovery of HIV, together with Françoise Barre-Sinoussi.

He is the author or co-author of 350 scientific publications and of more than 150 patents.


Elizabeth Mumper M.D., FAAP

Pediatrician and President and CEO of The RIMLAND Center

Dr. Mumper is President and CEO of The RIMLAND Center, established to mentor clinicians interested in children with neurodevelopmental problems. Her general pediatrics practice is Advocates for Children. Advocates for Families is devoted to the care of children with autism and other neurodevelopmental problems.

She attended the Medical College of Virginia, did residency training at the University of Massachusetts and University of Virginia, and she served as Chief Resident of Pediatrics at UVA.

Her clinical experience has included five years in pediatric practice, over a decade as Director of Pediatric Education in a Family Practice Residency Program, 16 years as clinical faculty at the University of Virginia, and five years as Medical Director of the Autism Research Institute. She is currently on the faculty of MAPS (Medical Academy for Pediatric Special Needs), and recently obtained certification from the Institute of Functional Medicine.

Dr. Mumper has been named a Miracle Maker in Central Virginia, Woman of the Year in Health and Sciences by the YWCA and received several Inspiring Change Awards from the MINDD Foundation in Australia. Dr. Mumper has written book chapters about allergy, immunology and behavioral and developmental pediatrics. Her clinical research at the Rimland Center has been published in peer reviewed journals. She lectures nationally and internationally and mentors physicians around the world, including Australia, Austria, Canada, the Czech Republic, Costa Rica, Denmark, Germany, Hong Kong, Italy, Japan, Mexico, New Zealand, Norway, Poland, Sweden, Switzerland, Thailand, and the United Kingdom.

She is currently doing research about vaccination status as it relates to the prevalence of chronic illness in children.  She advocates integrative and functional medicine strategies to care for children with complex chronic illness.


Jacob Puliyel M.D., MRCP, MPhil

Pediatrician and Director Programmes and Research Holy Family Hospital Delhi

Dr. Puliyel MD, is a pediatrician, post-graduate teacher and researcher who has worked in India and the UK. He worked on the health economics of vaccines for his MPhil in Health Systems Management. He was a member of the National Technical Advisory Group on Immunization (NTAGI) of the Government of India, advising national policy on vaccines and immunization.

He is at present the Director of Research and Projects at Holy Family Hospital in Delhi. Prior to this, he was Head of Pediatrics at St Stephens Hospital Delhi. He has over 160 publications in peer reviewed journals. His most recent work is on natural immunity to chickenpox with mother to baby transfer of varicella DNA.